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Abstract
Background: Poland Syndrome (PS) is a rare congenital malformation involving functional and aesthetic
impairments. Early diagnosis and timely therapeutic approaches play an important role in improving the quality of
life of patients and kindred. This study aims to explore healthcare experiences of the diagnosis of patients affected
by PS and to investigate the factors associated with diagnostic delay in Italy.
Results: Seventy-two patients affected by PS were asked to fill in a self- administered questionnaire on: a)
diagnostic path; b) perceived quality of care received after diagnosis; c) knowledge of the rights and the socio-
economic hardships related to their disease; d) evaluation of the integration of various professional skills involved in
the diagnostic and therapeutic approach; e) perception of the social support provided by the Italian Association of
Poland Syndrome (AISP). The average age at diagnosis was around 14 years; diagnosis was made at birth in only
31.58% of cases. Although typical symptomatology had appeared on average at an early age (4 months), only 23
patients (40.35%) received an early diagnosis (within the first year of life). Just over half of the patients (n = 30) were
diagnosed in their region of origin, while 27 were diagnosed elsewhere. Furthermore, 12.28% were self-diagnoses.
Among the patients who were diagnosed outside their region, 15 (88.24%) stated they had foregone some visits or
treatments owing to costs and/or organizational issues.
Conclusions: An analysis of the patients’ experiences highlights several gaps and a lack of homogeneity in the
diagnostic and therapeutic follow-up of PS patients in Italy. A specific national diagnostic and therapeutic path is
essential to guarantee patients complete and appropriate health services, compliant with the ethical principles of
non-discrimination, justice and empathy. Implementation of an effective information and research network and
empowerment of patients’ associations are necessary conditions to encourage clinical collaboration and improve
the quality of life of people living with rare diseases.
Keywords: Poland syndrome, Breast asymmetry, Chest malformation, Hand malformation, Congenital malformation,
Rare disease, Underdiagnosed patients
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Background
Poland Syndrome (PS) is a rare congenital condition char-
acterized by unilateral, partial or complete lack of the pec-
toralis major. Various rib cage deformities, ipsilateral hand
anomalies and ipsilateral breast hypoplasia or agenesis
may be observed [1–3]. According to the National Human
Genome Research Institute, PS affects males three times
more often than females and affects the right side of the
body twice as often as the left [4]. The incidence ranges
from one out of 7000 to one out of 100,000 live births [5].
Despite various hypotheses, the pathogenic mechanism
underlying PS is still unknown [6, 7]. So, despite the
greater access to comprehensive genetic testing, patients
with PS, as individuals with only suspected genetic
condition, often undertake the “diagnostic odyssey” char-
acterized by years of clinical, radiological, genetic and la-
boratory testing. During their diagnostic odyssey,
emotional distress and frustration in parents and adult pa-
tients have been observed [8–11]. The parents of patients
without a diagnosis feel uncertain about the future of their
children because they lack information on how to manage
the symptoms that arise. On the other hand, adult patients
seeking a diagnosis hope to be able to improve their qual-
ity of life. The diagnosis, in fact, can be considered a start-
ing point towards treatment options, thus reducing
uncertainty [12]. Moreover, receiving a correct diagnosis
and benefiting from appropriate genetic counseling is cru-
cial for planning future pregnancies, both for parents and
patients, through an informed choice about their repro-
ductive options [13]. Early diagnosis also plays an import-
ant role in scheduling a timely therapeutic approach.
Patients affected by PS, for example, need to correct hand
deformities [14] during childhood to reduce functional
impairment. Severe chest/breast asymmetries [2] need to
be addressed during adolescence to avoid negative body
perception which may lead to permanent insecurities and
the development of body-image disorders [15].
To date, in Italy, PS is often unrecognized, and only
two regions, both of which are in Northern Italy (Liguria
and Lombardy), have formally published a specific
Diagnostic and Therapeutic Care Paths (PDTA) and are
able to offer patients complete and appropriate health
services [16, 17]. There is little or no information on
how well the healthcare needs of people living with PS
in Italy are being met. Thus, the first aim of this study
was to explore the experiences of a group of Italian pa-
tients affected by PS with regard to diagnosis and care.
The second aim was to investigate the factors associated
with diagnostic delay in Italy.
Methods
The study involved 72 PS patients from various Italian
regions, who underwent examination (either their first
or for follow-up) during two national meetings focused
on patients affected by PS, which were held in Genova
in 2016. While in the waiting room, adult patients (≥ 18
yo) and caregivers of underage patients were asked to fill
in an anonymous, voluntary, self-administered, multiple-
choice questionnaire (Table 1). The final version was
composed of 26 questions (83 items) and was divided
into “demographic information” (age, sex, region of ori-
gin, respondent) and 5 other sections: a) the first section
“Diagnostic Path” referred to the timing of both the ap-
pearance of symptoms and confirmation of the diagno-
sis, to the healthcare facility and to the region where the
diagnosis was confirmed; b) the second section “Quality
of Care after Diagnosis” inquired about the respondents’
degree of difficulty in identifying a specialist for treat-
ment, the perceived quality of healthcare services for PS,
the impact of the difficulties they encountered, the pres-
ence of a reference healthcare provider during the treat-
ment period and the feeling of being understood; c) the
third section “Rights and Socio-economic Hardships en-
countered” asked respondents to indicate if and how
they became aware of their health rights, if they took ad-
vantage of health-cost exemption and if it was sufficient,
if they felt protected by the Italian NHS and if they had
been forced to forgo some treatments; d) the fourth sec-
tion “Collaboration among Health Care Professionals”
asked respondents to rate the involvement of pediatri-
cians, general practitioners and specialists in the diag-
nostic and therapeutic approach; e) the fifth section
“Associative Support and Activities” investigated the per-
ception of the usefulness of a patients’ association and
the role of the Italian Association of Poland Syndrome
(AISP) throughout the patients’ care path, their own per-
sonal registration and participation in association activ-
ities and, finally, the usefulness of medical meeting days
dedicated to PS; f) the last section “Scientific Research”
investigated the patients’ opinions on the scientific re-
search activities promoted by the association.
The questionnaire was designed by a panel of experts
on PS who were members of either the scientific com-
mittee (clinicians) or of the executive committee (pa-
tients or parents of affected patients who are volunteers
of the association) of AISP. The questionnaire was spe-
cifically designed to detect the difficulties encountered
by patients suffering from PS in the diagnostic and
therapeutic care path in Italy and thus to develop tar-
geted actions. Clinicians, supported by a bioethicist,
drew up a draft of the survey composed of 41 questions
and 150 items. The other experts (patients or parents of
affected patients) were asked to rate each question and
each item of the survey by assigning a score of 0, 1, 2 or
3 (0 = not pertinent and not explicit; 1 = not pertinent
but explicit; 2 = pertinent but not explicit; 3 = pertinent
and explicit). Those that were rated as “0” or “1” were
removed, while those rated “2” were modified. In the
Baldelli et al. Orphanet Journal of Rare Diseases          (2019) 14:269 Page 2 of 15
end, 15 questions were removed and 8 items were modi-
fied. Given the originally envisioned internal use for
which the questionnaire was created, no other validation
or reliability methods were applied.
Statistical analysis
Continuous variables are presented as means with stand-
ard deviations (SD), and categorical variables as numbers
of subjects and percentage values. If patients received
the diagnosis of PS in the region where they lived, the
region was classified as “IN” otherwise as “OUT”. The
diagnosis time was classified as “EARLY” (PS diagnosis
within the first year of life) or “LATE” (PS diagnosis after
the first year of life). Moreover, the region where PS pa-
tients lived was grouped into “Liguria, Lombardia”,
where an official PDTA for PS is present, or “Others”.
Univariate Penalized Logistic Regression models were
implemented in order to screen the effect of clinical and
demographic variables on the region of diagnosis and on
the diagnosis time. The odds ratio associated with the
region of diagnosis, and their 95% confidence intervals,
were calculated for each factor from the Logistic model.
The Likelihood Ratio (LR) test was used to test statistical
significance. Covariates with a p-value < 0.05 were then
selected for multivariate analysis, in which the region of
diagnosis and the diagnosis time were the dependent
variables. Multivariate analysis was also performed by
the Penalized Logistic Regression model, and model
selection was carried out using the Akaike Information
Criterion (AIC). Differences with a p-value < 0.05 were
deemed significant, and data were acquired and analyzed
in the R v3.5.1 software environment [18].
Results
The study involved 72 PS patients or caregivers who were
asked to fill in a questionnaire, 57 (23 adults, 34 minors)
of whom provided enough information to warrant evalu-
ation. The demographic and clinical characteristics of the
study participants are summarized in Table 2. Briefly, the
mean age at the time of filling in the questionnaire was
24.52 ± 16.91 years; 25 patients (43.86%) were males and
32 (56.14%) were females. The patients were all born in
Italy and came from 14 of the 20 Italian regions. Just over
half of the patients (N = 30) received their PS diagnosis in
their own region, while 27 had been diagnosed outside
their region of origin. The average age at diagnosis was
around 14 years; the diagnosis was made at birth in only
Table 1 Questions from the questionnaire, divided by topic
group
A) DIAGNOSTIC PATH
• Time of Diagnosis: when was the diagnosis confirmed?
• Who Diagnosed: who made the diagnosis?
• Region of Diagnosis: was the diagnosis made in your home region?
• Time of Symptoms Onset: at what age did the first signs of Poland
syndrome appeare?
B) QUALITY OF CARE AFTER DIAGNOSIS
• Difficulty to Find a Specialist for Treatment: Did you find it difficult to
identify a specialist to treat your condition?
• Quality of Treatment: How do you feel that your disease is being
treated?
• Impact: What impact did the difficulties you encountered in the
treatment course have on you?
• Reference Figure during Treatment: Did you know who to refer to
during the course of treatment?
• Feeling Understood during Treatment: Did you feel understood by
the doctor during the communication process?
C) RIGHTS AND SOCIO-ECONOMIC HARDSHIP ENCOUNTERED
• Knowledge of tax Exemption: Are you aware of the possibility of
accessing health benefits in relation to your condition?
• How Found Out About Exemption: How did you access the benefits
of exemption and / or disease monitoring?
• Exemption: have you been given an exemption for your condition?
• Sufficiency of the Exemption: Does the exemption fully cover the
diagnostic and therapeutic needs of your condition?
• Feeling of Protection: do you feel sufficiently protected by the health
care structure of your region?
• Forgo Treatment: have you ever forgone some visits or treatments
because of the costs or organizational issues you encountered?
D) COLLABORATION AMONG HEALTH CARE PROFESSIONALS
• General Practitioners _Pediatrician Role: How was the relationship
with your general practitioner / pediatrician during the diagnostic and
therapeutic clinical course?
• Collaboration: did your family doctor and specialist collaborate with
each other?
E) ASSOCIATIVE SUPPORT AND ACTIVITIES
• AISP Usefulness: Do you think a patient’s association is useful for your
pathology?
• AISP Advantage in care: Do you think that AISP has somehow
facilitated your treatment path?
• Join AISP: Are you enrolled in the Italian association of Poland
syndrome?
• Participate in AISP Activities: do you participate in the activities of the
association?
• PolandDay Usefulness: Do you think AISP promotes your relationship
with the various health services and operators?
F) SCIENTIFIC RESEARCH
• Volunteer: Would you like to contribute as a volunteer, even
occasionally, to the activities of the Association?
• Research: Do you think that scientific research is important in finding
the cause of Poland syndrome?
Table 1 Questions from the questionnaire, divided by topic
group (Continued)
• GeneticDonation: Would you donate your genetic material for
research?
• Family involvement in genetic research: Would you share the results
of genetic tests and research with your family members?
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Table 2 Demographic and clinical characteristics of study
participants (n = 57). The results are expressed as mean with
standard deviation or as number of subjects with percentage
Characteristic Overall























NEONATOLOGY UNIT 10 (17.54%)
PEDIATRICIAN 4 (7.02%)
GENERAL PRACTITIONER 1 (1.75%)






Time of Symptoms Onset
AT BIRTH 52 (91.23%)
1 YEAR 1 (1.75%)
3 YEARS 2 (3.51%)
6 YEARS 1 (1.75%)
7 YEARS 1 (1.75%)
Difficulty Finding a Specialist for Treatment
NO 29 (50.88%)
YES 26 (45.61%)
DON’T KNOW 2 (3.51%)
Table 2 Demographic and clinical characteristics of study
participants (n = 57). The results are expressed as mean with










NOT MY CASE 24 (42.11%)
NONE 20 (35.09%)
IMPORTANT PSY IMPACT 11 (19.3%)
MILD PSY IMPACT 1 (1.75%)
FUNCTIONAL IMPAIRMENT 1 (1.75%)
OTHER –
Reference Figure during Treatment
NO 16 (28.07%)
YES 33 (57.89%)
DON’T KNOW 8 (14.04%)
Feeling Understood during Treatment
NO 10 (17.54%)
YES 42 (73.68%)
DON’T KNOW 5 (8.77%)
Knowledge of tax Exemption
NO 3 (5.26%)
YES 54 (94.74%)
How They Found Out about Exemption
GENERAL PRACTITIONER 8 (14.81%)
REGIONAL BOOKING MEDICAL CENTER –
AISP 28 (51.85%)











DON’T KNOW 18 (31.58%)
Forgo Treatment
NO 33 (57.89%)
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31.58% of cases. Although the typical symptomatology of
the syndrome appeared on average at an early age (4
months), only 23 patients (40.35%) had received an early
diagnosis (within the first year of life). Despite the difficul-
ties encountered in obtaining a diagnosis, 45.61% of those
interviewed rated the overall quality of care received after
diagnosis as good, while 28.07% considered it excellent.
However, almost half of the respondents reported having
suffered some consequences because of the difficulties
they encountered in the diagnostic path, two thirds of
whom (35.09%) reported them as being of a psychological
nature. Almost all the patients reported having been in-
formed of the existence of a specific exemption from pay-
ment of the costs related to their pathology; however,
29.82% reported that they had waived health care on ac-
count of costs and/or organizational issues. The inter-
viewees acknowledged the important role of AISP in
facilitating the healthcare path (73.68%) and considered
AISP to be useful (91.23%), while a marginal role (not sig-
nificant = 38.6%; absent = 40.35%) was attributed to gen-
eral practitioners.
Influence of the region of origin on diagnosis and care
Table 3 reports the statistic output of demographic and
clinical factors related to the possibility of receiving the
diagnosis in or out of the region of origin: among pa-
tients who were diagnosed outside their region, 15
(88.24%) stated they had forgone some visits or treat-
ments owing to costs and/or organizational issues. The
majority of PS patients (12 (85.71%)) that lived in Liguria
or Lombardia received a PS diagnosis in a healthcare fa-
cility in their region, while 25 out of 43 (58.14%) patients
who lived in the other Italian regions were diagnosed
with PS outside their region of origin (p = 0.0041).
Univariate logistic regression analysis was carried out on
the complete set of data and is shown in Table 3. Multi-
variate analysis (Table 4) confirmed a statistically signifi-
cant effect regarding time to diagnosis confirmation, the
region of Italy where patients live and having to forgo
visits and treatments, and on the possibility of receiving
the diagnosis out of the region of origin (p-values: 0.0350,
0.0075 and 0.0016, respectively). In particular, the chance of
having the diagnosis out of the region of origin was about 4
times more likely in patients who had a “late confirmed
diagnosis” than that in patients with an “early confirmed
diagnosis” (OR (95%C.I.) = 4.10 (1.10 : 18.05)). Patients not
living in Liguria or Lombardia were about 8 times more
Table 2 Demographic and clinical characteristics of study
participants (n = 57). The results are expressed as mean with




DON’T KNOW 7 (12.28%)
General Practitioner _Pediatrician’s Role
FUNDAMENTAL 5 (8.77%)
QUITE RELEVANT 7 (12.28%)
NOT VERY RELEVANT 22 (38.6%)








DON’T KNOW 4 (7.02%)
AISP Advantage in Care
NO 3 (5.26%)
YES 42 (73.68%)














DON’T KNOW 31 (54.39%)
Research
YES 56 (98.25%)
DON’T KNOW 1 (1.75%)
Genetic Donation
YES 52 (91.23%)
DON’T KNOW 5 (8.77%)
Family Involvement in Genetic Research
NO 4 (7.02%)
YES 43 (75.44%)
Table 2 Demographic and clinical characteristics of study
participants (n = 57). The results are expressed as mean with
standard deviation or as number of subjects with percentage
(Continued)
Characteristic Overall
DON’T KNOW 10 (17.54%)
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Table 3 Contingency tables and summary output of the univariate analysis. Characteristic: variable taken into account; OR (95% CI):
Odds Ratio with 95% Confidence Interval; p-value: Likelihood Ratio p-value. aVariables entering the multivariate analysis (see the text
for abbreviations and further details)
Characteristic Descriptive statistics Univariate analysis
RegionDgn OR (95%C.I.) p-value
IN OUT
Gender 0.0958
MALE 10 (40%) 15 (60%) 1
FEMALE 20 (62.5%) 12 (37.5%) 0.41 (0.14: 1.17)
Macro Regiona 0.0041
LIGURIA, LOMBARDIA 12 (85.71%) 2 (14.29%) 1
OTHERS 18 (41.86%) 25 (58.14%) 6.89 (1.78: 38.57)
Time of Diagnosisa 0.0372
EARLY 16 (69.57%) 7 (30.43%) 1
LATE 14 (41.18%) 20 (58.82%) 3.11 (1.07: 9.70)
Who Diagnoseda 0.0045
NEONATOLOGY UNIT 9 (90%) 1 (10%) 1
PEDIATRICIAN 3 (75%) 1 (25%) 2.71 (0.18: 43.60)
GENERAL PRACTITIONER 0 (0%) 1 (100%) 19 (0.69: 3428.71)
SPECIALIZED MED CENTRE 6 (27.27%) 16 (72.73%) 16.08 (2.84: 173.45)
SELF-DIAGNOSIS 2 (28.57%) 5 (71.43%) 13.93 (1.73: 197.59)
OTHER 10 (76.92%) 3 (23.08%) 2.11 (0.28: 24.78)
Time of Symptoms Onset 0.9999
AT BIRTH 0 (NaN%) 0 (NaN%) 1
LATER 3 (60%) 2 (40%) 1 (0.02: 60.68)
Difficulty Finding a Specialist for Treatment 0.6585
NO 17 (58.62%) 12 (41.38%) 1
YES 12 (46.15%) 14 (53.85%) 1.62 (0.57: 4.71)
DON’T KNOW 1 (50%) 1 (50%) 1.4 (0.1: 18.82)
Quality of Treatment 0.5953
EXCELLENT 8 (50%) 8 (50%) 1
GOOD 16 (61.54%) 10 (38.46%) 0.64 (0.18: 2.17)
SUFFICIENT 3 (42.86%) 4 (57.14%) 1.29 (0.24: 7.45)
UNSATISFACTORY 3 (50%) 3 (50%) 1 (0.16: 6.08)
OTHER 0 (0%) 2 (100%) 5 (0.34: 731.03)
Impact 0.6293
NOT MY CASE 13 (54.17%) 11 (45.83%) 1
NONE 8 (40%) 12 (60%) 1.73 (0.54: 5.73)
IMPORTANT PSY IMPACT 7 (63.64%) 4 (36.36%) 0.70 (0.16: 2.84)
MILD PSY IMPACT 1 (100%) 0 (0%) 0.39 (0.00: 8.09)
FUNCTIONAL IMPAIRMENT 1 (100%) 0 (0%) 0.39 (0: 8.09)
Reference Figure during Treatment 0.9440
NO 9 (56.25%) 7 (43.75%) 1
YES 17 (51.52%) 16 (48.48%) 1.19 (0.37: 3.94)
DON’T KNOW 4 (50%) 4 (50%) 1.27 (0.25: 6.63)
Feeling Understood during Treatment 0.8257
NO 6 (60%) 4 (40%) 1
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Table 3 Contingency tables and summary output of the univariate analysis. Characteristic: variable taken into account; OR (95% CI):
Odds Ratio with 95% Confidence Interval; p-value: Likelihood Ratio p-value. aVariables entering the multivariate analysis (see the text
for abbreviations and further details) (Continued)
Characteristic Descriptive statistics Univariate analysis
RegionDgn OR (95%C.I.) p-value
IN OUT
YES 21 (50%) 21 (50%) 1.44 (0.38: 5.90)
DON’T KNOW 3 (60%) 2 (40%) 1.03 (0.12: 7.95)
Knowledge of tax Exemption 0.6776
NO 2 (66.67%) 1 (33.33%) 1
YES 28 (51.85%) 26 (48.15%) 1.55 (0.19: 17.75)
How They Found Out about Exemption 0.6893
GENERAL PRACTITIONER 5 (62.5%) 3 (37.5%) 1
REGION BOOKING MEDICAL CENTER 14 (50%) 14 (50%) 1.57 (0.35: 7.92)
AISP 6 (42.86%) 8 (57.14%) 2.05 (0.39: 12.06)
REFERENCE MEDICAL CENTER 3 (75%) 1 (25%) 0.67 (0.05: 6.64)
Exemption 0.8995
NO 6 (54.55%) 5 (45.45%) 1
YES 24 (52.17%) 22 (47.83%) 1.09 (0.30: 4.02)
Sufficiency of the Exemption 0.5038
NO 5 (41.67%) 7 (58.33%) 1
YES 15 (53.57%) 13 (46.43%) 0.64 (0.16: 2.38)
Feeling of Protection 0.0691
NO 10 (37.04%) 17 (62.96%) 1
YES 9 (75%) 3 (25%) 0.22 (0.05: 0.88)
DON’T KNOW 11 (61.11%) 7 (38.89%) 0.39 (0.11: 1.27)
Forgo Treatmenta 0.0003
NO 23 (69.7%) 10 (30.3%) 1
YES 2 (11.76%) 15 (88.24%) 13.88 (3.47: 80.21)
DON’T KNOW 5 (71.43%) 2 (28.57%) 1.02 (0.16: 5.08)
General Practitioner _Pediatrician’s Role 0.3299
FUNDAMENTAL 2 (40%) 3 (60%) 1
QUITE RELEVANT 6 (85.71%) 1 (14.29%) 0.16 (0.01: 1.61)
LITTLE RELEVANT 11 (50%) 11 (50%) 0.71 (0.10: 4.42)
NONE 11 (47.83%) 12 (52.17%) 0.78 (0.11: 4.77)
Collaboration 0.9846
NO 21 (52.5%) 19 (47.5%) 1
YES 3 (50%) 3 (50%) 1.10 (0.21: 5.79)
DON’T KNOW 6 (54.55%) 5 (45.45%) 0.93 (0.25: 3.42)
AISP Usefulness 0.7134
NO 0 (0%) 1 (100%) 1
YES 28 (53.85%) 24 (46.15%) 0.29 (0: 5.63)
DON’T KNOW 2 (50%) 2 (50%) 0.33 (0: 10.12)
AISP Advantage in Care 0.6757
NO 2 (66.67%) 1 (33.33%) 1
YES 23 (54.76%) 19 (45.24%) 1.38 (0.17: 16.05)
DON’T KNOW 5 (41.67%) 7 (58.33%) 2.27 (0.23: 30.51)
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likely to be diagnosed out of their own region than patients
living in Liguria or Lombardia (OR (95%C.I.) = 8.17 (1.69:
60.72)). Moreover, taking patients that answered “no” to the
“Forgo Treatment” question as the reference group, the
chance of being diagnosed out of the region of origin was
about 12 times higher than in patients that had to give up
the necessary care (OR (95%C.I.) =11.59 (2.46: 84.32)).
Time needed for diagnosis
Table 5 reports the descriptive statistics of demographic
and clinical factors related to the time needed for diagno-
sis. With regard to early diagnoses (within the first year of
life), they were carried out in neonatology centers in
43.47% of cases. Specialized centers for rare diseases pro-
vided an early diagnosis in a further 30.43% of cases. On
the other hand, with regard to late diagnoses, they were
mainly carried out (44.12%) in specialized centres for rare
diseases (p-value = 0.0015). Moreover, 76.92% of patients
receiving a late diagnosis reported difficulties in finding a
specialist to take care of them, while only 23.08% of
Table 3 Contingency tables and summary output of the univariate analysis. Characteristic: variable taken into account; OR (95% CI):
Odds Ratio with 95% Confidence Interval; p-value: Likelihood Ratio p-value. aVariables entering the multivariate analysis (see the text
for abbreviations and further details) (Continued)
Characteristic Descriptive statistics Univariate analysis
RegionDgn OR (95%C.I.) p-value
IN OUT
Join AISP 0.4025
NO 5 (41.67%) 7 (58.33%) 1
YES 25 (55.56%) 20 (44.44%) 0.59 (0.16: 2.03)
Participate in AISP Activities 0.6365
NO 17 (50%) 17 (50%) 1
YES 13 (56.52%) 10 (43.48%) 0.78 (0.27: 2.21)
PolandDayUsefulness 0.3722
No or Partial 3 (37.5%) 5 (62.5%) 1
YES 27 (55.1%) 22 (44.9%) 0.52 (0.11: 2.18)
Volunteer 0.2516
NO 3 (42.86%) 4 (57.14%) 1
YES 13 (68.42%) 6 (31.58%) 0.37 (0.06: 2.00)
DON’T KNOW 14 (45.16%) 17 (54.84%) 0.94 (0.18: 4.51)
Research 0.5067
YES 29 (51.79%) 27 (48.21%) 1
DON’T KNOW 1 (100%) 0 (0%) 0.36 (0.00: 7.00)
Genetic Donation 0.2339
YES 26 (50%) 26 (50%) 1
DON’T KNOW 4 (80%) 1 (20%) 0.33 (0.03: 1.96)
Family Involvement in Genetic Research 0.5371
NO 1 (25%) 3 (75%) 1
YES 23 (53.49%) 20 (46.51%) 0.37 (0.03: 2.50)
DON’T KNOW 6 (60%) 4 (40%) 0.3 (0.02: 2.58)
Table 4 Multivariate analysis, the predictor effects on the
diagnosis region (N = 57). Results are expressed as odds ratio
(OR) with 95% confidence interval (95%CI); p-value: Likelihood
Ratio p-value
Characteristic OR (95%C.I.) p-value
(Intercept) 0.04 (0: 0.25) 0.0001
Time of Diagnosis 0.0350
EARLY 1
LATE 4.10 (1.10: 18.05)
Macro Region 0.0075
LIGURIA, LOMBARDIA
OTHERS 8.17 (1.69: 60.72)
Forgo Treatment 0.0016
NO 1
YES 11.59 (2.46: 84.32)
DON’T KNOW 0.54 (0.07: 3.12)
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Table 5 Contingency tables and summary output of the univariate analysis. Characteristic: variable taken into account; OR (95% CI):
Odds Ratio with 95% Confidence Interval; p-value: Likelihood Ratio p-value. aVariables entering the multivariate analysis (see the text
for abbreviations and further details)
Characteristic Descriptive statistics Univariate analysis
Time of Diagnosis OR (95%C.I.) p-value
EARLY LATE
Gender 0.1182
MALE 13 (52%) 12 (48%) 1
FEMALE 10 (31.25%) 22 (68.75%) 2.31 (0.81: 6.86)
Macro Region 0.7131
LIGURIA, LOMBARDIA 5 (35.71%) 9 (64.29%) 1
OTHERS 18 (41.86%) 25 (58.14%) 0.8 (0.23: 2.62)
Region of Diagnosisa 0.0372
IN 16 (53.33%) 14 (46.67%) 1
OUT 7 (25.93%) 20 (74.07%) 3.11 (1.07: 9.7)
Who Diagnoseda 0.0015
NEONATOLOGY UNIT 10 (100%) 0 (0%) 1
PEDIATRICIAN 2 (50%) 2 (50%) 21 (1.22: 3297.07)
GENERAL PRACTITIONER 0 (0%) 1 (100%) 63 (1.55: 22813.53)
SPECIALIZED MED CENTRE 7 (31.82%) 15 (68.18%) 43.4 (4.52: 5865.49)
SELF-DIAGNOSIS 1 (14.29%) 6 (85.71%) 91 (6.1: 14644.97)
OTHER 3 (23.08%) 10 (76.92%) 63 (5.62: 8933.3)
Time of Symptoms Onset 0.3965
AT BIRTH 22 (42.31%) 30 (57.69%) 1
LATER 1 (20%) 4 (80%) 2.21 (0.37: 23.2)
Difficulty Finding a Specialist for Treatmenta 0.0193
NO 17 (58.62%) 12 (41.38%) 1
YES 6 (23.08%) 20 (76.92%) 4.42 (1.46: 14.66)
DON’T KNOW 0 (0%) 2 (100%) 7 (0.51: 998.96)
Quality of Treatment 0.5070
EXCELLENT 7 (43.75%) 9 (56.25%) 1
GOOD 13 (50%) 13 (50%) 0.79 (0.23: 2.67)
SUFFICIENT 2 (28.57%) 5 (71.43%) 1.74 (0.31: 12)
UNSATISFACTORY 1 (16.67%) 5 (83.33%) 2.89 (0.44: 32.89)
OTHER 0 (0%) 2 (100%) 3.95 (0.27: 577.44)
Impacta 0.0160
NOT MY CASE 15 (62.5%) 9 (37.5%) 1
NONE 4 (20%) 16 (80%) 5.98 (1.7: 24.58)
IMPORTANT PSY IMPACT 2 (18.18%) 9 (81.82%) 6.2 (1.38: 38.2)
MILD PSY IMPACT 1 (100%) 0 (0%) 0.54 (0: 11.32)
FUNCTIONAL IMPAIRMENT 1 (100%) 0 (0%) 0.54 (0: 11.32)
Reference Figure during Treatment 0.8297
NO 6 (37.5%) 10 (62.5%) 1
YES 13 (39.39%) 20 (60.61%) 0.94 (0.27: 3.08)
DON’T KNOW 4 (50%) 4 (50%) 0.62 (0.12: 3.22)
Feeling Understood during Treatment 0.5698
NO 3 (30%) 7 (70%) 1
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Table 5 Contingency tables and summary output of the univariate analysis. Characteristic: variable taken into account; OR (95% CI):
Odds Ratio with 95% Confidence Interval; p-value: Likelihood Ratio p-value. aVariables entering the multivariate analysis (see the text
for abbreviations and further details) (Continued)
Characteristic Descriptive statistics Univariate analysis
Time of Diagnosis OR (95%C.I.) p-value
EARLY LATE
YES 17 (40.48%) 25 (59.52%) 0.68 (0.15: 2.65)
DON’T KNOW 3 (60%) 2 (40%) 0.33 (0.04: 2.54)
Knowledge of tax Exemption 0.2009
NO 0 (0%) 3 (100%) 1
YES 23 (42.59%) 31 (57.41%) 0.19 (0: 2.12)
How They Found Out about Exemptiona 0.0468
GENERAL PRACTITIONER 7 (87.5%) 1 (12.5%) 1
REGION BOOKING MEDICAL CENTER 10 (35.71%) 18 (64.29%) 8.81 (1.6: 92.23)
AISP 4 (28.57%) 10 (71.43%) 11.67 (1.78: 137.63)
REFERENCE MEDICAL CENTER 2 (50%) 2 (50%) 5 (0.45: 80.16)
Exemption 0.1047
NO 2 (18.18%) 9 (81.82%) 1
YES 21 (45.65%) 25 (54.35%) 0.31 (0.06: 1.26)
Sufficiency of the Exemption 0.1556
NO 3 (25%) 9 (75%) 1
YES 14 (50%) 14 (50%) 0.37 (0.08: 1.45)
Feeling of Protection 0.1048
NO 8 (29.63%) 19 (70.37%) 1
YES 8 (66.67%) 4 (33.33%) 0.23 (0.05: 0.9)
DON’T KNOW 7 (38.89%) 11 (61.11%) 0.67 (0.19: 2.3)
Forgo Treatment 0.3773
NO 16 (48.48%) 17 (51.52%) 1
YES 5 (29.41%) 12 (70.59%) 2.14 (0.66: 7.62)
DON’T KNOW 2 (28.57%) 5 (71.43%) 2.07 (0.43: 12.88)
General Practitioner _Pediatrician ‘s Role 0.2250
FUNDAMENTAL 4 (80%) 1 (20%) 1
QUITE RELEVANT 2 (28.57%) 5 (71.43%) 6.6 (0.71: 99.65)
LITTLE RELEVANT 10 (45.45%) 12 (54.55%) 3.57 (0.54: 39.93)
NONE 7 (30.43%) 16 (69.57%) 6.6 (1: 74.93)
Collaboration 0.2571
NO 18 (45%) 22 (55%) 1
YES 3 (50%) 3 (50%) 0.82 (0.16: 4.32)
DON’T KNOW 2 (18.18%) 9 (81.82%) 3.12 (0.76: 17.93)
AISP Usefulness 0.767
NO 0 (0%) 1 (100%) 1
YES 22 (42.31%) 30 (57.69%) 0.45 (0: 8.88)
DON’T KNOW 1 (25%) 3 (75%) 0.78 (0: 28.48)
AISP Advantage in Care 0.1429
NO 2 (66.67%) 1 (33.33%) 1
YES 19 (45.24%) 23 (54.76%) 2.01 (0.25: 23.32)
DON’T KNOW 2 (16.67%) 10 (83.33%) 7 (0.65: 109.9)
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patients receiving early diagnosis reported this sort of dif-
ficulty (p-value = 0.0193). Univariate logistic regression
analysis carried out on the complete set of data is shown
in Table 5. Multivariate analysis (Table 6) confirmed the
statistically significant effect of difficulty in identifying a
specialist for treatments, having received the diagnosis in-
side or outside the region of origin and AISP’s role in
promoting relationships with health services and opera-
tors on time needed for confirmed diagnosis (p-values:
0.0154, 0.0497 and 0.0114, respectively). Specifically,
the probability of a delayed diagnosis was 5 times
higher in patients who had difficulty in identifying a
specialist who could provide treatment (OR (95%C.I.) =5.23
(1.48: 21.25)). Moreover, a late PS diagnosis was 3.5 times
more likely in patients who were diagnosed outside their
region of origin than in those diagnosed inside their region,
(OR (95%C.I.) =3.54 (1.01: 14.27)). Finally, a delay in
diagnosis was about 94% less likely in patients who
considered medical days dedicated to PS useful than in
the others (OR (95%C.I.) = 0.06 (0.00: 0.58)) (Fig. 1).
Table 5 Contingency tables and summary output of the univariate analysis. Characteristic: variable taken into account; OR (95% CI):
Odds Ratio with 95% Confidence Interval; p-value: Likelihood Ratio p-value. aVariables entering the multivariate analysis (see the text
for abbreviations and further details) (Continued)
Characteristic Descriptive statistics Univariate analysis
Time of Diagnosis OR (95%C.I.) p-value
EARLY LATE
Join AISP 0.2438
NO 3 (25%) 9 (75%) 1
YES 20 (44.44%) 25 (55.56%) 0.46 (0.1: 1.67)
Participate in AISP Activitiesa 0.0103
NO 9 (26.47%) 25 (73.53%) 1
YES 14 (60.87%) 9 (39.13%) 0.24 (0.08: 0.72)
PolandDay Usefulnessa 0.0095
No or Partial 0 (0%) 8 (100%) 1
YES 23 (46.94%) 26 (53.06%) 0.07 (0: 0.58)
Volunteer 0.4363
NO 2 (28.57%) 5 (71.43%) 1
YES 6 (31.58%) 13 (68.42%) 0.94 (0.14: 5.3)
DON’T KNOW 15 (48.39%) 16 (51.61%) 0.48 (0.08: 2.36)
Research 0.6361
YES 23 (41.07%) 33 (58.93%) 1
DON’T KNOW 0 (0%) 1 (100%) 2.1 (0.11: 312.63)
Genetic Donation 0.0715
YES 19 (36.54%) 33 (63.46%) 1
DON’T KNOW 4 (80%) 1 (20%) 0.19 (0.02: 1.15)
Family Involvement in Genetic Research 0.3269
NO 2 (50%) 2 (50%) 1
YES 15 (34.88%) 28 (65.12%) 1.84 (0.26: 13.04)
DON’T KNOW 6 (60%) 4 (40%) 0.69 (0.08: 6.17)
Table 6 Multivariate analysis, the predictor effects on the time
needed for diagnosis (N = 57). Results are expressed as odds
ratio (OR) with 95% confidence interval (95%CI); p-value:
Likelihood Ratio p-value
Characteristic OR (95%C.I.) p-value
(Intercept) 4.35 (0.4: 594.1) 0.2624




YES 5.23 (1.48: 21.25)
DON’T KNOW 13.45 (0.81: 2064.32) 0.0497
Region of Diagnosis
IN 1
OUT 3.54 (1.01: 14.27)
PolandDay Usefulness 0.0114
NO OR PARTIAL 1
YES 0.06 (0: 0.58)
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Discussion
According to the World Health Organization (WHO)
Constitution, “the enjoyment of the highest attainable
standard of health is one of the fundamental rights of
every human being”. However, the decades-long diag-
nostic odysseys for many rare diseases patients has
scarcely been studied [19]: guaranteeing that all people
living with a rare disease may receive an accurate and
prompt diagnosis is generally agreed upon as being an
urgent need [20].
Previous studies have reported that available treat-
ments and care for rare diseases are varied and heteroge-
neous, reflecting political, economic and geographic
differences among countries [21]. The health care system
in Italy is a regionally based national health service
known as Servizio Sanitario Nazionale (SSN). While the
national health service ensures that the general objec-
tives and fundamental principles of the national health
care system are met, the regional governments in Italy
are responsible for ensuring the delivery of a benefits
package to the population. They are autonomous and
are responsible for organizing networks for patients with
rare diseases [22].
The main aims of our study were to assess the potential
link between the geographic origin of patients and time
spent before obtaining a PS diagnosis, and to evaluate the
quality of the received treatments. Data on patients’ expe-
riences of diagnostic path reported in our research show a
lower diagnostic threshold than those reported in the sur-
vey carried out by the European Organisation for Rare
Diseases (Eurordis) on eight heterogeneous rare diseases
in 2007 [23]. In particular, Italian patients with PS had to
travel to a location outside of their home region to obtain
the diagnosis almost twice as often as European rare dis-
eases patients. We can assume that the diagnostic odyssey
of Italian patients with PS is not only due to the lack of
adequately trained healthcare professionals and dedicated
health facilities in the area where patients affected by PS
are born, but also to the the lack of knowledge about the
services that are available for PS patients by health profes-
sionals even in regions where an official PDTA has already
been released. Although appropriate clinical facilities are
already in place, diagnosis can still be delayed, thus con-
firming the limited awareness by the general population.
Our data show that receiving a correct diagnosis in
one’s own region is essential for the therapeutic continu-
ity, which means that the patient can be appropriately
followed-up by the regional health system. Italian pa-
tients affected by PS have reported similar experiences
to those identified internationally among people living
with rare diseases, their caregivers and families [24].
Failure to obtain a correct diagnosis is an onerous ex-
perience for patients and their families as they are forced
to consult numerous physicians and to undergo many,
often expensive, consultations and clinical tests, a situ-
ation which causes psychological distress and conse-
quently, additional stress [25]. Furthermore, without a
diagnosis, the patient’s medical or social needs may not
receive adequate attention thereby creating the feeling of
being “invisible” [26]. Taken together, these aspects
affect the responsible participation by the patient in the
therapeutic path that represents an important factor
both for adults and for minors, which was recently en-
hanced in Italy by specific legislation [27, 28].
Fig. 1 Bar-Plot of the Time of Diagnosis, Macro Region and Forgo Treatment in the Region of Diagnosis
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The positive correlation between logistic regression ana-
lysis and the patient’s engagement in AISP (which in-
cludes participation in social activities as well as access to
a dedicated psychological support plan and to consult-
ation with physicians specifically trained in PS) is abso-
lutely in line with the litterature [29] and can be explained
by items that include confidence and empathy, which may
be pivotal in influencing subjective well-being rating more
than any other clinical symptom of PS.
Our finding of a significant correlation between the pa-
tients’ decision to forgo follow-up healthcare programs
and the patients’ region of origin corroborates the results
of previous studies on rare diseases [30]. Accordingly, the
physical distance from high-quality health services may
directly impact upon the patient’s social, psychological,
and occupational functioning. The ethical principles of
non-discrimination, justice, equity and solidarity require
adequate consideration, as does the protection of the
needs of individuals with rare diseases and their families
[31]. Taken together, the paucity of specific health policies
for rare diseases, the scarcity of skills, the lack of a na-
tional support plan and of specific training programs re-
sult in delayed diagnoses, difficulties in accessing care,
inadequate treatment, increased physical discomfort,
socio-psychological issues for patients and their families
and, finally, in a loss of confidence in the public health
system [32]. The all too frequent difficulty in finding a
specialist who can confirm the diagnosis, regardless of the
patient’s region of origin, may partly be ascribed to the ab-
sence of a specific national plan and to the lack of ex-
change of knowledge and information within a structured
and coordinated network. In line with previous studies, we
agree that the lack of adequate information and training
programs, as well as of a national medical network able to
offer consultancy support, leaves the general practitioner
with a marginal role and increases the number of self-
diagnoses [24]. As already reported, drawing up multidis-
ciplinary integrated paths is crucial in order to allow med-
ical staff to share care protocols based on best practices
and to ensure adequate and effective treatment for pa-
tients with a rare disease [33].
As confirmed by this study, patient advocacy organiza-
tions (PAOs) currently play a key role in the manage-
ment of patients seeking a clinical reference, thereby
improving the assistance and the quality of life of people
living with a rare disease [34, 35]. Our study was de-
signed with the cooperation of AISP to identify the main
issues concerning the health services available to Italian
patients with Poland syndrome. Based on the analysis of
our data, in fact, AISP then took targeted actions to
strengthen care services in southern and central Italy by
organizing two informative clinical events in Puglia
(“The network for care and research” - San Giovanni
Rotondo (Foggia), 25th November, 2017) and in Emilia
Romagna (“Open Day on Poland Syndrome” – Modena,
13th October, 2018). Involving health facilities which
have all the medical specializations that are needed to
support the affected patients eventually led to the birth
of two new centres of reference for the diagnosis and
treatment of patients with Poland Syndrome.
When interpreting our data, we have to consider some
limitations. First of all, only patients with an overall good
attitude towards being surveyed took part in the study
and filled in the questionnaire exhaustively. Moreover,
the sample size is rather small and does not include pa-
tients from all Italian regions. Furthermore, given the
heterogeneity of the patients’ age, questionnaires were
filled in by caregivers in case of minors, while adult pa-
tients filled in the questionnaire autonomously. Differ-
ences between self- and proxy-completed responses on
health status surveys are well described in the literature
[36, 37]. For example, some studies have reported that
parents tend to assign a lower score on health-related
quality of life questions regarding their children with a
chronic health condition [38–40]. However, the accuracy
of the responses is strictly linked to the degree of confi-
dence the proxy respondent has with the presented is-
sues. In our study, the topics we investigated mainly
concern objective questions whose answers are probably
best known by the patients’ parents. Lastly, we did not
thoroughly assess the real reasons for forgoing treatment
by patients who had previously been receiving appropriate
support. A further extension of this study based on qualita-
tive interviews with patients, clinicians and other stake-
holders (such as AISP members) will allow us to acquire
more details and explanations of the phenomenon and will
re-evaluate health services for Italian patients suffering from
Poland syndrome taking into account the activity of the
two new strategically located Italian reference centers.
Conclusions
This study underlines that the healthcare needs of people
living with PS are not being fully met in Italy. Our analysis
of patients’ experiences highlights many gaps and a lack of
homogeneity in the diagnostic and therapeutic path of PS
patients in our country. The implementation of an effect-
ive information network to promote research, stimulate
clinical collaboration and improve the quality of life of
people with rare diseases in general is, to date, predomin-
antly supported by PAOs.
Adequate empowerment of PAOs within the National
Health Service and the institutional bodies where health
policies are defined would allow these volunteer associa-
tions to evolve from merely being a voice of the short-
comings of the public sector to a key player within the
territory; this synergy would thus result in a greater ap-
plication of the principle of subsidiarity.
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